Skip to main content
OpenTrials
Completed

NCT Number: NCT04377724

Spread and Course of COVID-19 Infections

The overall goal is to study the immune response to SARS-CoV-2 infection over the period of one year in the blood of a representative cohort of ETH students/employees.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Disease Virus Diseases

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Observational

Primary location

ETH

Zurich, 8092, Switzerland

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ETH employee or ETH student and their family members living in the same household at the start of the study
  • Between 18 and 64 years of age at the start of the study
  • Signed informed consent

Exclusion criteria

  • Age over 64 years at the start of the study
  • In quarantine or self-confinement at the start of the study
  • Active COVID-19 infection at the start of the study:
  • Diagnosed with a laboratory test
  • Suspected based on typical symptoms such as fever (>38°C), acute pulmonary ex-acerbation or sudden loss of gustatory taste
  • The following medical condition
  • With continuous steroid therapy/ chemotherapy/immunsuppressive therapy
  • In treatment for cancer
  • With severe autoimmune disease

Treatment and study plan

Primary outcomes

  1. seroprevalence as well as the titer of serum antibodies (IgM, IgG and IgA) targeting SARS-CoV-2 antigens

    Time frame: 12 months

Secondary outcomes

  1. the property of peripheral blood mononuclear cells before and after an infection with SARS-CoV-2 as opposed to other pathogens

    Time frame: 12 months

  2. the property of IgM and IgA antibody titers against the nucleocapsid protein of SARS-CoV-2 in symptomatic as well as asymptomatic COVID-19 infections over the course of time following an infection

    Time frame: 12 months

  3. the immune response to common-cold (corona)virus and influenza virus infections in patients with COVID-19 infections

    Time frame: 12 months

Sponsors and collaborators

Lead sponsor

Goldhahn Jörg

Other

Registry information

Official study title

Longitudinal Serological Study on the Spread and Course of COVID-19 Infections

Acronym: CoV-ETH

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
May 6, 2020
Registry last updated
Feb 23, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.